Is Beam Therapeutics Inc. (BEAM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.7% / 30% | 46.1% / 30% | 0.0% / 30% | 186.03% / 5% | ✗ NOT HALAL |
| DJIM | 5.7% / 33% | 46.1% / 33% | 0.0% / 33% | 186.03% / 5% | ✗ NOT HALAL |
| MSCI | 10.4% / 33% | 84.1% / 33% | 0.0% / 33% | 186.03% / 5% | ✗ NOT HALAL |
| S&P | 5.7% / 33% | 46.1% / 33% | 0.0% / 33% | 186.03% / 5% | ✗ NOT HALAL |
| FTSE | 10.4% / 33% | 84.1% / 33% | 0.0% / 50% | 186.03% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -193.1% | |
| Operating Margin | -15.3% | |
| Net Margin | -57.2% | |
| Return on Equity (ROE) | -8.1% | |
| Return on Assets (ROA) | -18.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$345M |
| Free Cash Flow | -$360M |
| Total Debt | $154M |
| Debt-to-Equity | 12.4 |
| Current Ratio | 13.1 |
| Total Assets | $1.5B |
Price & Trading
| Last Close | $23.62 |
| 50-Day MA | $27.53 |
| 200-Day MA | $23.87 |
| Avg Volume | 1.8M |
| Beta | 2.2 |
|
52-Week Range
$13.53
| |
About Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Beam Therapeutics Inc. (BEAM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Beam Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Beam Therapeutics Inc.'s debt ratio?
Beam Therapeutics Inc.'s debt ratio is 5.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.4%.
What are Beam Therapeutics Inc.'s key financial metrics?
Beam Therapeutics Inc. has a market capitalization of $2.3B, and revenue of $140M. The company maintains a gross margin of -193.1% and a net margin of -57.2%. Return on equity stands at -8.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.